Skip to main content
. 2017 Sep 16;8(49):86206–86216. doi: 10.18632/oncotarget.21039

Figure 3. Effects of YC-1 on protein levels of plasminogen activator inhibitor-1 (PAI-1) and osteopontin (OPN) in the BDL mice.

Figure 3

Immunohistochemical analysis of liver sections from BDL or BDL plus YC-1-treated mice. The expression of PAI-1 (A) and OPN (C) were analyzed using PAI-1 or OPN antibodies, respectively. Immunoblot analysis of total liver lysates of BDL mice. BDL leads to a significant increase in PAI-1 (B) or OPN (D) protein levels, whereas YC-1 treatment shows more prominent changes. Equal amounts of lysate from sham or BDL mice were loaded in each lane and normalized against the control β-actin. The results are presented as the mean ± SEM from three independent experiments. (*p < 0.05 vs. sham; #p < 0.05 vs. BDL.)